| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
DocGo Inc. Common Stock
$0.58
-0.05 (-8.29%)
Market Cap
57.45 M
EPS
-1.89
P/E Ratio
-
Value Trade
495.52 K
SEC Financials
Q1 2026Dilution Risk
Revenue
75.55 M
R&D Expenses
3.71 M
Operating CF
-4.66 M
Total Assets
209.23 M
Total Liabilities
98.02 M
Equity
132.31 M
-8.58 %
Week
-7 %
1 Month
0.12 %
3 Month
-18.65 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
46.82 M
Monthly Burn
1.55 M
Runway
27.3 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
194.87 K
52 Week Range
0.45 - 1.76
% held by Insiders
6.52 %
% held by Institutions
40.53 %
Enterprise Value
12.84 M
Total Shares
98.78 M
Short %
2.41 %
Float Shares
95.82 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DCGO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DCGO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-DCGO
Aug 10, 2026▼ -8.3%today
DocGo to Announce Second Quarter 2026 Results on Monday, August 17, 2026
DocGo Inc. will announce its financial results for the second quarter of 2026 on August 17, 2026, after market close. The company will also host a conference call at 5:00 p.m. ET to discuss these results. This event highlights DocGo's commitment to keeping investors informed about its performance.
Read more →-DCGO
Jun 3, 2026▼ -8.4%on this news
DocGo Launches Mobile Phlebotomy Services in South Florida
DocGo has introduced mobile phlebotomy services in South Florida. This initiative aims to enhance patient convenience and accessibility to blood collection services. The launch reflects DocGo's commitment to expanding its healthcare offerings in the region. Further details on the operational aspects and expected impact were not provided.
Read more →-DCGO
May 26, 2026DocGo Announces Upcoming Participation at the Goldman Sachs 47th Annual Global Healthcare Conference
DocGo will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. The event is a significant opportunity for the company to engage with investors and discuss its strategic initiatives. Further details on the presentation and topics to be covered are yet to be announced.
Read more →-DCGO
May 11, 2026DocGo Announces First Quarter 2026 Results
DocGo has announced its financial results for the first quarter of 2026. However, the article does not provide specific details about the performance metrics or any significant developments during this period. The lack of detailed information limits the analysis of the company's current standing and future prospects.
Read more →-DCGO
May 11, 2026DocGo Announces First Quarter 2026 Results Company Increases 2026 Revenue Guidance Based on Strong Demand for Virtual Care Services Management to Host Conference Call and Webcast Today at 5 00 PM Eastern Time NEW YORK, N
DocGo Inc. announced its first quarter results for 2026, highlighting a total revenue of $75.6 million, which reflects a steady growth excluding the wind-down of certain migrant-related programs. The company's revenue guidance for 2026 has been updated upward due to strong demand for virtual care services, with specific business lines reporting record volumes. However, the company is also facing challenges, showing an increase in net losses compared to the previous year. Management remains optimistic about future performance, expecting improvements in adjusted EBITDA as operational efficiencies are implemented.
Read more →-DCGO
May 6, 2026▼ -9%on this newsshared move
DocGo Announces Upcoming Participation at the 21st Annual Needham Technology, Media, & Consumer Conference
DocGo Inc. announced its participation in the 21st Annual Needham Technology, Media, & Consumer Conference, where CEO Lee Bienstock will present. The event is scheduled for May 14, and a webcast will be available on their investor relations website. DocGo focuses on technology-enabled medical transportation and mobile health services.
Read more →-DCGO
Apr 27, 2026DocGo to Announce First Quarter 2026 Results on Monday, May 11, 2026
DocGo Inc. will announce its financial results for Q1 2026 on May 11, 2026, after market close. A conference call will follow at 5:00 p.m. ET to discuss these results. The company focuses on technology-enabled medical transportation and mobile health services, aiming to enhance patient care and operational efficiencies.
Read more →-DCGO
Mar 16, 2026DocGo Announces Fourth Quarter and Full Year 2025 Results Company Raises 2026 Revenue and Adjusted EBITDA Guidance due to Customer Expansions, Improved EMS Hiring Rates and Efficiency Initiatives Company Has Initiated a
DocGo Inc. has reported its financial results for the fourth quarter and full year of 2025, revealing a decline in total revenue primarily due to the end of migrant-related programs. The company raised its revenue and adjusted EBITDA guidance for 2026, anticipating growth driven by new expansions and efficiency initiatives. Despite a significant net loss and financial impairments in 2025, management remains optimistic about improving margins and profitability in the upcoming year, supported by their core healthcare services.
Read more →-DCGO
Nov 10, 2025DocGo Announces Third Quarter 2025 Results Company Achieves Record Volumes Across All Major Business Lines Management to Host Conference Call and Webcast Today at 5 00 PM Eastern Time
DocGo Inc. reported its financial results for the third quarter of 2025, highlighting a significant decline in total revenue due to the winding down of migrant-related programs. Despite a decrease in overall revenue, the company announced record volumes across all major business lines, with particular growth in transportation services and mobile health. However, DocGo also faced a substantial net loss compared to the same quarter last year, which included non-cash impairments. Looking ahead, the company provided guidance for 2026, projecting increased revenues from its core services, excluding migrant-related programs.
Read more →-DCGO
Sep 30, 2025DocGo Acquires Virtual Care Platform SteadyMD, Expands Telehealth Services Across all 50 States Strategic Acquisition Combines DocGo's Last Mile Healthcare Delivery Capabilities With SteadyMD's Virtual Care Platform; Ste
DocGo has announced its acquisition of SteadyMD, a virtual care platform, to enhance its telehealth services across all 50 states. This strategic acquisition aims to combine DocGo's mobile healthcare delivery with SteadyMD's virtual care capabilities, targeting a revenue generation of approximately $25 million in 2025. The integration is expected to streamline patient care delivery and access to healthcare services. Key officials from SteadyMD will join DocGo's leadership team to drive the combined operations forward.
Read more →-DCGO
Aug 7, 2025DocGo Announces Second Quarter 2025 Results Company Reiterates 2025 Revenue and Adjusted EBITDA Guidance, Increases Total Cash Balance to $128.7 Million, Signs New Contracts Across All Business Verticals Management to Ho
DocGo Inc. reported its second quarter 2025 financial results, indicating a decline in total revenue to $80.4 million compared to the previous year, largely due to the planned wind-down of migrant-related programs. Despite a net loss of $13.3 million, the company increased its cash balance to $128.7 million and continued to sign new contracts across various business sectors. Key corporate highlights included surpassing 1.2 million patients engaged for care gap closure services and launching new programs aimed at enhancing health service delivery. The company reaffirmed its revenue guidance for the full year 2025.
Read more →-DCGO
May 8, 2025DocGo Announces First Quarter 2025 Results Company Focuses on Growing Medical Transportation and Payer Provider Businesses, Navigates Municipal Uncertainty and Migrant Services Transition Management to Host Conference Ca
DocGo Inc. has reported its financial results for the first quarter of 2025, indicating significant challenges primarily due to municipal uncertainties and a strategic shift away from non-migrant government health services. Revenue decreased to $96.0 million from $192.1 million year-over-year, with an anticipated adjusted EBITDA loss of $20-$30 million. Despite this, the company achieved record medical transportation metrics and aims to grow through new partnerships and service expansions, while planning to reduce operational expenditures.
Read more →-DCGO
Feb 27, 2025DocGo Announces Fourth Quarter and Full-Year 2024 Results Company Surpasses 700,000 Total Patient Lives Assigned for Care Gap Closure Programs and Expands Contracts With Payer Partners on Both Coasts Management to Host C
DocGo Inc. (DCGO) reported its financial results for the fourth quarter and full year of 2024, highlighting a revenue decrease primarily attributed to the wind-down of migrant-related programs. The company surpassed 700,000 patient lives in its care gap closure initiatives and expanded its contracts with healthcare partners. Despite these achievements, DocGo faced a net loss in Q4 2024 and lower adjusted EBITDA than anticipated, signaling challenges in transitioning from migrant services to core mobile health revenue. Management is optimistic about future growth and believes ongoing investments will drive the company's success moving forward.
Read more →-DCGO
Nov 7, 2024DocGo Announces Third Quarter 2024 Results Company Significantly Expands Operations on the West Coast to Support New Payer Programs, Increases Full-Year Guidance for Cash Flow from Operations Management to Host Conferenc
DocGo Inc. reported its third quarter 2024 financial results with notable changes. Total revenue decreased 26% due to the winding down of migrant-related programs, while net income showed a minimal decline. However, the company increased its full-year guidance for cash flow from operations and expanded its West Coast operations to support new payer programs. Key performance indicators, including adjusted EBITDA and cash flow, demonstrated positive trends despite the challenges faced in revenue from specific services.
Read more →-DCGO
Sep 30, 2024DocGo Appoints Healthcare Visionary Dr. Stephen K. Klasko as Chair of the Board
DocGo Inc. has appointed Dr. Stephen K. Klasko as the new independent, non-executive Chair of its Board of Directors, effective October 1, 2024. Dr. Klasko brings extensive experience in healthcare leadership, including roles at Thomas Jefferson University and Jefferson Health. His appointment is seen as a strategic move to enhance DocGo's mobile health services and value-based care strategies, with the company positioned for growth in the healthcare sector. Outgoing Chair Steven Katz will assist in the transition as a consultant.
Read more →-DCGO
Aug 7, 2024DocGo Announces Strong Second Quarter 2024 Results Company Raises Cash Flow From Operations Guidance to $80-$90 Million, Reiterates 2024 Revenue Guidance of $600-$650 Million and Adjusted EBITDA 1 Guidance of $65-$75 Mil
DocGo Inc. reported strong financial results for the second quarter of 2024, with a revenue increase of 31% year-over-year. The company raised its guidance for cash flow from operations to $80-$90 million and reaffirmed its revenue estimate for the year between $600-$650 million. Adjusted EBITDA also saw a significant rise, up 89% to $17.2 million. In addition, DocGo secured new contracts and expanded services, further positioning itself for growth in the mobile health sector.
Read more →-DCGO
May 8, 2024DocGo Announces Strong First Quarter 2024 Results Company Reports First Quarter Net Income of $10.6 Million and Record Adjusted EBITDA 1 of $24.1 Million Management to Host Conference Call and Webcast Today at 5 00 PM Ea
DocGo Inc. reported strong financial results for the first quarter of 2024, including a net income of $10.6 million and record adjusted EBITDA of $24.1 million. Total revenue surged to $192.1 million, indicating a 70% year-over-year increase. Despite these positive results, the company revised its 2024 revenue guidance downwards due to the accelerated wind-down of its migrant-related services, expecting revenue between $600 and $650 million. DocGo remains optimistic about the growth of its core business in mobile health and medical transportation services.
Read more →-DCGO
Feb 28, 2024Document DocGo Announces Record Fourth Quarter and Full-Year 2023 Results Company Updates 2024 Revenue Guidance to $720-$750 Million, Introduces 2024 Adjusted EBITDA Guidance 1 of $80-$85 Million Management to Host Confe
DocGo announced record financial results for the fourth quarter and full year of 2023, with revenues increasing significantly compared to the previous year. The company expects 2024 revenues to range between $720-$750 million and has introduced adjusted EBITDA guidance of $80-$85 million. Despite these achievements, DocGo faced challenges with decreased gross margins and a substantial drop in net income due to rising costs and tax expenses. Management remains optimistic about future growth driven by new partnerships and program expansions.
Read more →-DCGO
Jan 31, 2024▲ +8.5%on this news
DocGo Announces Share Buyback Program
DocGo Inc. has announced a new share buyback program allowing for the repurchase of up to $36 million worth of its common stock over a six-month period. This decision follows the expiration of a previous buyback authorization and reflects the company's confidence in its value despite a recent decline in stock price. The buyback aims to enhance shareholder value and will be influenced by various market conditions. The program is set to begin after the current blackout period ends in early March 2024.
Read more →-DCGO
Jan 16, 2024Document DocGo Provides Additional Information to Refute Misleading Short Seller "Report" NEW YORK - (Business Wire)
DocGo Inc. has publicly rebutted allegations made by short seller Fuzzy Panda Research, claiming the report misrepresents facts and is intended for financial gain at the expense of DocGo's stakeholders. The company asserts it maintains a robust compliance framework and has consistently achieved strong financial performance. Additionally, independent audits have verified the adequacy of DocGo's services for its contracts, further strengthening its position against the claims. DocGo emphasizes transparency and commitment to ethical operations while continuing to support its business growth.
Read more →-DCGO
Jan 10, 2024▼ -37.6%on this newsshared move
Document DocGo Rejects Short Seller Report and Releases Preliminary 2024 Revenue Guidance NEW YORK - (Business Wire)
DocGo Inc. has rejected a critical report from Fuzzy Panda Research, asserting the claims made are misleading and defamatory. The company anticipates its revenue for fiscal year 2024 will surpass $700 million, signaling continued growth amid the controversies. Additionally, DocGo holds a strong compliance program to validate its billing practices and responds positively to support from its partners. Plans for further detailed financial guidance will be provided with the upcoming Q4 2023 results.
Read more →-DCGO
Nov 6, 2023DocGo Announces Record Third Quarter 2023 Results Company Raises 2023 Revenue Guidance to $615-$625 Million, up From a Previous Range of $540-$550 Million And Increases Adjusted EBITDA 1 Guidance to $50-$55 Million, up F
DocGo Inc. reported record financial results for Q3 2023, with total revenue reaching $186.6 million, a substantial increase of 49% from the previous quarter. The company raised its full-year revenue guidance to $615-$625 million, driven by significant growth across its business lines. Despite a decrease in gross margin and cash balances, net income and adjusted EBITDA showed notable improvements, underscoring the company's operational success. Furthermore, a substantial increase in the workforce reflects ongoing demand for DocGo's services.
Read more →-DCGO
Sep 6, 2023▼ -7.5%on this news· ran to -20% by day 3
ADOLFO CARRIÓN JR. Commissioner Office of the Commissioner 100 Gold Street New York, N.Y. 10038
Adolfo Carrión Jr., Commissioner, addressed a letter regarding a contract between DocGo and the Department of Housing Preservation and Development in New York. The letter assured that despite a communication from the New York City Comptroller indicating potential issues, payments under the contract will continue as planned. The HPD intends to clarify with the Comptroller that all necessary steps will be taken to ensure compliance and prompt payment. This communication reflects ongoing collaborative efforts to manage the migrant crisis effectively.
Read more →-DCGO
Aug 7, 2023DocGo Announces Record Second Quarter 2023 Results Company Raises 2023 Revenue Guidance To $540-$550 Million Increases Adjusted EBITDA 1 Guidance To $48-$53 Million
DocGo Inc. (NASDAQ: DCGO) has announced impressive financial results for the second quarter of 2023, reporting record revenues with guidance raised to between $540 million and $550 million for the full year. The company's adjusted EBITDA guidance also saw an increase to between $48 million and $53 million. Growth in core markets and strong demand from large payers have been pivotal in these results. Additionally, DocGo indicated an improved gross margin, reflecting operational efficiency and ongoing strategic investments.
Read more →-DCGO
Jun 20, 2023Proactive Health Care Revolution 05 06 07 08 Excellence In Operations Care Delivery Growth Trajectory Clinical Excellence Q&A Technology Executing Our Vision AGENDA Cautionary Note Regarding Forward - Looking Statements
DocGo Inc. (DCGO) has outlined its proactive healthcare model aimed at improving care delivery and reducing hospital admissions. The company anticipates over 30% annual revenue growth in the coming years, driven by its innovative services that address chronic healthcare issues. DocGo capitalizes on a strong financial position to support its expansion into various healthcare sectors. The presentation also highlights the company's mission to modernize and enhance healthcare accessibility across the United States.
Read more →-DCGO
May 8, 2023DocGo Announces First Quarter 2023 Results Company Reiterates 2023 Revenue Guidance of $500-$510 million and Adjusted EBITDA 1 Guidance of $45-$50 million NEW YORK, NY , May 8th, 2023 - DocGo Inc. (Nasdaq: DCGO), a leadi
DocGo Inc. announced its financial results for the first quarter of 2023, reaffirming its revenue guidance of $500-$510 million and adjusted EBITDA guidance of $45-$50 million for the year. The company expressed optimism about its growth prospects, indicating an increase in backlog and successful agreements with several healthcare providers. Despite initial gross margin pressures due to startup costs, recent improvements in operations suggest a positive trend toward achieving a targeted gross margin of 37% by year-end. DocGo's strategy centers on providing last-mile mobile health services, enhancing patient care through innovative technology.
Read more →-DCGO
Mar 13, 2023DocGo Announces Fourth Quarter and Full-Year 2022 Results 2022 Revenue Increased to $440.5 Million, Versus $318.7 Million in 2021, an Increase of 38% Full Year Revenue up 75% Year-Over-Year Excluding Mass Covid Testing C
DocGo Inc. (Nasdaq: DCGO) announced its financial results for the fourth quarter and full year of 2022, reporting a revenue increase to $440.5 million, marking a 38% growth from the previous year. The company anticipates revenue for 2023 to be between $500-510 million, reflecting growth despite the exclusion of non-recurring COVID testing revenue. DocGo's leadership expressed confidence in continued demand for mobile health services and highlights a backlog of $180 million in new contracts. However, they also noted significant costs associated with new projects, which negatively impacted gross margins.
Read more →-DCGO
Dec 29, 2022DocGo Announces Stan Vashovsky to Continue to Serve as Chairman of its Board of Directors NEW YORK (
Announces Stan Vashovsky to Continue to Serve as Chairman of its Board of Directors 29, 2022) - (Business Wire) - DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services, announced today that its co-founder and current Chairman of the Board and Chief
Read more →-DCGO
Nov 14, 2022▲ +6.4%on this news
DocGo Appoints Veteran Technology Human Resources Executive Vina Leite, MS, to its Board of Directors and Announces Key Leadership Promotions NEW YORK (
DocGo Appoints Veteran Technology Human Resources Executive Vina Leite, MS, to its Board of Directors and Announces Key Leadership Promotions NEW YORK (Nov. 14, 2022) - (Business Wire) - DocGo (Nasdaq: DCGO), a leading provider of last-mile mobile health services, today anno
Read more →-DCGO
Nov 7, 2022DocGo Announces Strong Third Quarter 2022 Results Q3 Revenue of $104.3 Million Up 22% Year-Over-Year; Company Raises Full-Year 2022 Revenue and Adjusted EBITDA Guidance Co-founder and CEO Stan Vashovsky announces his ret
DocGo Announces Strong Third Quarter 2022 Results Q3 Revenue of $104.3 Million Up 22% Year-Over-Year; Company Raises Full-Year 2022 Revenue and Adjusted EBITDA Guidance Co-founder and CEO Stan Vashovsky announces his retirement effective December 31st; DocGo President Anthony
Read more →-DCGO
Nov 2, 2022▼ -7%on this news· ran to -21% by day 3shared move
DocGo Announces $90 Million Line of Credit with Citibank, N.A. Available funds to be used for opportunistic M&A and working capital as needed NEW YORK (
Announces $90 Million Line of Credit with Citibank, N.A. funds to be used for opportunistic M&A and working capital as needed YORK (Nov. 2, 2022) - (Business Wire) - DocGo (Nasdaq: DCGO), a leading provider of last-mile mobile health services, today announced that it has enter
Read more →-DCGO
Aug 15, 2022DocGo Announces Redemption of All Outstanding Warrants
DocGo Announces Redemption of All Outstanding NEW YORK - August 15, 2022 - DocGo Inc. , a leading provider of last-mile mobile health services and integrated ambulance medical transportation solutions (Nasdaq: DCGO), announced today that it will redeem all of its outstanding
Read more →-DCGO
Aug 8, 2022DocGo Announces Strong Second Quarter 2022 Results Q2 Revenue of $109.5 Million Up 76% Year-Over-Year; Company Raises Full-Year 2022 Guidance
DocGo Announces Strong Second Quarter 2022 Results Q2 Revenue of $109.5 Million Up 76% Year-Over-Year; Company Raises Full-Year 2022 Guidance NEW YORK, NY, August 8, 2022 - DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services, today announced fina
Read more →-DCGO
May 24, 2022DocGo Announces Share Repurchase Program of Up To $40 Million
DocGo Announces Share Repurchase Program of May 24, 2022 - (New York, NY) - DocGo (Nasdaq: DCGO), a leading provider of last-mile mobile health services and integrated medical transportation solutions, announced today that its Board of Directors has authorized a share repurcha
Read more →-DCGO
May 9, 2022DocGo Announces Strong First Quarter 2022 Results Q1 Revenue of $118 Million Up 137% Over Comparable Prior Year Period Bolsters Senior Staff, Expands Market Footprint
DocGo Announces Strong First Quarter 2022 Q1 Revenue of $118 Million Up 137% Over Comparable Bolsters Senior Staff, Expands Market Footprint NEW YORK, NY, May 9, 2022 - DocGo (Nasdaq:DCGO), a leading provider of last-mile mobile health services and integrated medical transpor
Read more →-DCGO
Mar 14, 2022▼ -6.5%on this news· ran to +31% by day 3
DocGo Names Lee Bienstock as Chief Operating Officer to Drive Strategic Expansion Bienstock joins DocGo from Google, where he most recently served as Global Head of Enterprise Partnerships, Devices
DocGo Names Lee Bienstock as Chief Operating Officer to Drive Strategic Expansion Bienstock joins DocGo from Google, where he most recently served as Global Head of Enterprise Partnerships, Devices and Services NEW YORK, March 14, 2022-DocGo, a leading provider of last-mile
Read more →-DCGO
Mar 14, 2022▼ -6.5%on this news· ran to +31% by day 3
DocGo Announces Record Fourth Quarter and Full Year 2021 Results Q4 and full year revenue increased 289% and 239%, respectively, over comparable prior year periods Positive adjusted EBITDA and net income for both the qua
DocGo Announces Record Fourth Quarter and Full Year year revenue increased 289% and 239%, respectively, over comparable prior year periods Positive adjusted EBITDA and net income for both the quarter and full year NEW YORK, NY, March 14, 2022 - DocGo (Nasdaq:DCGO), a leading
Read more →-DCGO
Jan 28, 2022▲ +10.4%on this news· ran to +22% by day 3
DocGo Announces Record Preliminary Fourth Quarter 2021 Revenue Full year and fourth quarter revenue of $305.0 million and $107.8 million, respectively, more than triple versus prior year periods
Announces Record Preliminary Fourth Quarter 2021 Revenue year and fourth quarter revenue of $305.0 million and $107.8 million, respectively, more than versus prior year periods 28, 2022 -- (New York, NY) -DocGo, (Nasdaq: DCGO), a leading provider of last-mile mobile health ser
Read more →-DCGO
Dec 1, 2021DocGo Announces Increase in Full-Year 2021 Guidance Annual revenues expected to reach over $290 million, Adjusted EBITDA of at least $12 million
Increase in Full-Year 2021 Guidance expected to reach over $290 million, Adjusted EBITDA of at least $12 million 1, 2021 -- (New York, NY) - DocGo, a leading provider of last-mile mobile health services and integrated medical mobility solutions (Nasdaq:DCGO), announced today t
Read more →-DCGO
Nov 15, 2021Ambulnz, Inc. and Subsidiaries CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIODS ENDED SEPTEMBER 30, 2021 and 2020 Condensed Consolidated Balance Sheets as of
Ambulnz, Inc. and Subsidiaries CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIODS ENDED SEPTEMBER 30, 2021 and 2020 Condensed Consolidated Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020 2 Unaudited Condensed Consolidated Statements of Operat
Read more →-DCGO
Nov 12, 2021▲ +12.4%on this newsshared move
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K to which this Unaudited Pro Forma C
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K to which this Unaudited Pro Forma Condensed Combined Financial Information is attached (the "Form 8-K")
Read more →-DCGO
Nov 2, 2021Motion Acquisition Corp. and DocGo Announce Shareholder Approval Of Business Combination
Motion Acquisition Corp. and DocGo Announce Shareholder Approval Of Business Combination November 2, 2021 -- (New York, NY) - Motion Acquisition Corp. ("Motion") (Nasdaq: MOTN), a special purpose acquisition company, and its merger partner Ambulnz, Inc., dba DocGo, a leading
Read more →-DCGO
Jul 20, 2021Motion Acquisition Corp. and DocGo Announce DocGo's Record Preliminary Second Quarter 2021 Revenue Second quarter revenue increased 175% year-over-year DocGo raises full-year revenue outlook to at least $170 million
Motion Acquisition Corp. and DocGo Announce DocGo's Record Preliminary Second Quarter 2021 Second quarter revenue increased 175% year-over-year DocGo raises full-year revenue outlook to at least $170 million July 20, 2021 -- (New York, NY) - Motion Acquisition Corp. ("Motio
Read more →-DCGO
May 28, 2021MOTION Acquisition corp. RECEIVES NASDAQ NOTIFICATION OF NON-COMPLIANCE WITH LISTING RULES New York, New York
Acquisition corp. RECEIVES NASDAQ NOTIFICATION NON-COMPLIANCE WITH LISTING RULES New York, New York - May 28, 2021 - Motion Acquisition Corp. (NASDAQ: MOTN) ("Motion" or the "Company"), a blank check company formed for the purpose of effecting a merger, share exchange, asset
Read more →-DCGO
May 21, 2021A l l R i g h t s R e s e r v e d - D o c G o INVESTOR P R ESE N T A TIO N MAY 2021 WHERE TELEHEALTH STOPS, WE GO Disclaimer 2 0 2 1 A l l R i g h t s R e s e r v e d - D o c G o 1 This presentation contemplates a busine
2 0 2 1 A l l R i g h t s R e s e r v e d - D o c G o INVESTOR P R ESE N T A TIO N MAY 2021 WHERE TELEHEALTH STOPS, WE GO Disclaimer 2 0 2 1 A l l R i g h t s R e s e r v e d - D o c G o 1 This presentation contemplates a business combination pursuant to a merger agreement, by a
Read more →-DCGO
Apr 28, 2021Motion Acquisition Corp. and DocGo Announce DocGo's Record Preliminary First Quarter 2021 Results Revenue more than triples from prior year to $49 million DocGo raises full-year revenue outlook
Acquisition Corp. and DocGo Announce DocGo's Record Preliminary First Quarter 2021 Results than triples from prior year to $49 million full-year revenue outlook 28, 2021 /PRNewswire/ -- Motion Acquisition Corp. ("Motion") (Nasdaq: MOTN), a publicly traded special purpose acqu
Read more →-DCGO
Mar 9, 2021Ambulnz (dba DocGo), a Leading Provider of Last-Mile TeleHealth and Integrated Medical Mobility Services, Announces Agreement to Become Publicly Traded via Merger with Motion Acquisition Corp. DocGo leverages its technol
Ambulnz (dba DocGo), a Leading Provider of Last-Mile TeleHealth and Integrated Medical Mobility Services, Announces Agreement to Become Publicly Traded via Merger with Motion Acquisition Corp. NEW YORK - March 9, 2021 - Ambulnz, Inc., to be renamed DocGo, Inc. ("DocGo" or the
Read more →-DCGO
Mar 8, 2021Set forth below is a transcript of a recorded investor presentation, made by officers of Motion Acquisition Corp. and Ambulnz Inc. (dba DocGo), disseminated on
Set forth below is a transcript of a recorded investor presentation, made by officers of Motion Acquisition Corp. and Ambulnz Inc. (dba DocGo), disseminated on March 8, 2021. Michael Burdiek, CEO, Motion Acquisition Hello, I'm Michael Burdiek, CEO and Director of Motion Acqui
Read more →-DCGO
Oct 19, 2020MOTION ACQUISITION CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of October 19, 2020 F-3 Notes to Financial Statement F-4 of independent registered public accounting firm the Stockholders and the Board of Directors of Motion Acquisition Corp. on the Financial Stat
Read more →-DCGO
Oct 15, 2020Motion Acquisition Corp. Announces Pricing of $115,000,000 Initial Public Offering New York, NY
Acquisition Corp. Announces Pricing of $115,000,000 Initial Public Offering New York, NY, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Motion Acquisition Corp. (the "Company") announced today that it priced its initial public offering of 11,500,000 units at $10.00 per unit. The units wil
Read more →Competitive Position
How DCGO ranks across every disease it competes inCompetitive Position is a premium feature
See how DCGO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial